AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating a disorder by using a compound of formula (I)



(I)

wherein

(i) R^1 and R^2 are the same or different and are selected from H, $-CH_2-O-R^5$, $-CH_2-O-SO_2-R^5$, $-CH_2-S-R^5$, $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ and $-CH_2-O-CO-OR^5$;

R^3 is =O~~,~~;

R^4 and R^5 are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R^4 and R^5 in $-NR^4R^5$ are bonded together and form, together with the nitrogen atom

to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups;

with the proviso that when R^1 and R^2 are both $-CH_2-OR^5$ then both R^5 ~~is~~ are not H; and

with the further proviso that R^1 and R^2 are not both H; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form an substituted or non-substituted cyclic carbonate; wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl and non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR^6; $CONR^6R^7$; and $COOR^6$;

R^6 and R^7 are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the hetero-atoms are independently selected from N, O and S; or

~~as well as of~~ a pharmaceutically acceptable ~~salts~~ salt thereof,

for the treatment of a disorder selected from hyperproliferative diseases, by administering said compound in an effective amount for said disorder, to a patient in need thereof.

2. (Previously Presented) The method according to claim 1, wherein the disorder is a cancer.

3. (Currently Amended) A compound of formula (I)



(I)

wherein

(i) R^1 and R^2 are the same or different and are selected from H, $-CH_2OH$, $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ and $-CH_2-O-CO-OR^5$;

R^3 is =O~~, provided that at least one of R^1 and R^2 is selected from $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ and $-CH_2-O-CO-OR^5$~~;

R^4 and R^5 are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or

non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R^4 and R^5 in $-NR^4R^5$ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups;

with the proviso that R^1 and R^2 are not both selected from H and $-CH_2OH$; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate; wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR^6; $CONR^6R^7$; and $COOR^6$;

R^6 and R^7 are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-

C10 heterocyclyl wherein the hetero-atoms are independently selected from N, O and S; or

~~as well as~~ a pharmaceutically acceptable ~~salts~~ salt of the ~~compounds~~ compound of formula (I).

4. (Previously Presented) A process for the preparation of a compound according to claim 3 by reacting a compound of formula (I)



(I)

wherein

R^1, R^2 and R^3 are as defined in claim 3, provided that at least one of R^1 and R^2 is $-CH_2OH$; or wherein both R^1 and R^2 are $-CH_2OH$ and R^3 is as defined in claim 3;

with a compound of formula R^5-CO-X, NR^4R^5-CO-X, or R^5O-CO-X; wherein X is a leaving group; under conditions suitable for transforming at least one of R^1 and R^2 into $-CH_2$-O-CO-R^5, $-CH_2$-O-CO-NR^4R^5 or $-CH_2$-O-CO-OR^5 wherein R^4 and R^5 are as defined in claim 3;

or by reacting a compound of said formula (I) wherein both R^1 and R^2 are $-CH_2OH$; with a compound of formula



5. (Previously Presented) A compound according to claim 3 for use as a medicament.

6. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable excipient.

7. (Original) A pharmaceutical composition according to claim 6, comprising at least one further, pharmaceutically active compound.

8. (Cancelled)

9. (Previously Presented) A pharmaceutical composition according to claim 7, wherein the at least one further active compound *in vivo* is susceptible of reacting with glutathione.

10. (Currently Amended) A pharmaceutical composition according to~~,~~ claim 7 or claim 9, wherein the further pharmaceutically active compound is selected from adriamycin, melphalan and cisplatin.

11. (Currently Amended) A method of treatment of a disease selected from hyperproliferative diseases, by administration of a therapeutically effective amount of a compound of formula (I)



(I)

wherein

(i) R^1 and R^2 are the same or different and are selected from H, $-CH_2-O-R^5$, $-CH_2-O-SO_2-R^5$, $-CH_2-S-R^5$, $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ and $-CH_2-O-CO-OR^5$;

R^3 is =O~~,~~ ;

R^4 and R^5 are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-

substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R^4 and R^5 in $-NR^4R^5$ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups;

with the proviso that when R^1 and R^2 are both $-CH_2-OR^5$ then both R^5 ~~is~~ are not H; and

with the further proviso that when one of R^1 and R^2 is H and the other one is $-CH_2-NR^4R^5$, then R^4 and R^5 are not substituted or non-substituted monocyclic aryl; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate; wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR^6; $CONR^6R^7$; and $COOR^6$;

R^6 and R^7 are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-

C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or

~~as well as of~~ a pharmaceutically acceptable ~~salts or prodrugs~~ salt or prodrug thereof,

to a patient in the need of such treatment.

12. (Original) The method according to claim 11 wherein the compound of formula (I) is administered together with a further, pharmaceutically active compound.

13. (Cancelled)

14. (Currently Amended) The method according to the claim 12 wherein the further~~,~~ pharmaceutically active compound *in vivo* is susceptible of reacting with glutathione.

15. (Previously Presented) The method according to claim 12 or claim 14, wherein the further pharmaceutically active compound is selected from adriamycin, melphalan, cisplatin.

16. (Currently Amended) A method of treating a mammal suffering from a hyperproliferative disease,

comprising administering to said mammal in need thereof a therapeutically effective amount of a compound selected from the group consisting of:



		
		
		
		

 ,	 ,	 ,
 ,	 ,	 ,
 ,	 ,	 ,
 ,	 ,	 ,
 ,	 ,	 ,

 ,	 ,	 ,
 ,	 ,	 ,
and	 .	

17. (Previously Presented) The method according to claim 16, wherein the disorder is cancer.

18. (Currently amended) A compound selected from the group consisting of:

























		
		
		
		

 ,	and	 .

19. (Previously Presented) The process according to claim 4, wherein X is Cl.

20. (Previously Presented) The compound according to claim 3, wherein R^1 and R^2 are the same or different and are both selected from the group consisting of $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ and $-CH_2-O-CO-OR^5$.